M any in-hospital deaths among the neurocritically ill occur after limitation of life-sustaining therapies. Nationally, 13.5% to 15% of patients in neuro-ICUs have life-sustaining therapies withheld or withdrawn, and limitation of such therapies precedes up to 61% of all deaths in the neuro-ICU (1) (2) (3) . Though withdrawal of life-sustaining therapy (WOLST) is common, there is concern that pessimism among clinicians, especially early after brain injury, may lead to premature limitations of potentially life-saving therapies. Compounding this issue is the fact that many prognostic models that predict mortality after intracranial hemorrhage are confounded by the inclusion of WOLST patients (4) . Reliance on such prognostic tools may lead to a self-fulfilling prophecy and an inevitably fatal outcome. However, there is a need to rely on prognostic models to some extent as brain-injured patients make their maximal spontaneous recovery over 3-6 months (5) (6) (7) (8) . Neurologic examination changes that would affect prognosis and decision making often occur well after the ICU and hospital stay. In recognition of these concerns, the American Heart Association, together with the American Stroke Association, recommends that new do-not-resuscitate (DNR) orders be deferred and full intensive care therapy be administered after intraparenchymal hemorrhage (IPH) at least until the second day of hospitalization (9) .
Though some practitioners may be nihilistic with regard to prognosis, there are certain cases where death is highly probable, and early transition to comfort care or WOLST may be reasonable. Conversely, some physicians are overly optimistic when discussing prognosis (10) . The motivation for this optimism may be to maintain hope for recovery and/or avoid emotionally laden discussions with patients or surrogates. Unfortunately, there are no standardized guidelines to follow for decisions related to WOLST, and individual practices may vary widely between institutions (11) . Recent advances in neurocritical and palliative care may contribute to a more balanced goals-of-care decision-making process.
The purpose of this study was to determine whether WOLST in an intracranial hemorrhage population represents a self-fulfilling prophecy or whether the WOLST decision is being systematically applied to patients who are unlikely to experience a good outcome despite maximal medical and surgical treatment. We sought to evaluate the probability of in-hospital death or 12-month death/severe disability among WOLST patients had they continued receiving maximal medical and surgical therapy. We tested the hypothesis that our algorithm for deciding to withdraw support in patients with aneurysmal or CT-negative subarachnoid hemorrhage (SAH), subdural hematoma (SDH), and IPH would accurately identify patients with a high probability of death or severe disability at 1 year after admission. Accurate identification of patients who are likely to die despite maximal therapy may help facilitate discussions regarding earlier transition to WOLST to potentially shorten length of stay, lower hospital costs, and reduce patient and family suffering.
METHODS

Study Population
A retrospective analysis of prospectively collected data was performed on consecutive patients with aneurysmal or CTnegative SAH, SDH, and IPH admitted to a tertiary neuroscience ICU between August 2008 and October 2011. Criteria for inclusion in the study were defined as age 18 years old or older, intracranial hemorrhage onset within 14 days of admission, and consent to participate in 3-and 12-month follow-up interviews as part of a prospective cohort study investigating functional outcomes. A priori, we prospectively collected data on the WOLST decision to determine the predictors of WOLST. Exclusion criteria included traumatic SAH, SAH secondary to vascular dissection, vasculopathy, arteriovenous malformation, or other nonaneurysmal causes. The diagnosis of intracranial hemorrhage was based on admission CT scan data and/or lumbar puncture in the case of CT-negative SAH. This study was approved by the local institutional review board. All patients or their surrogates were consented for participation in this study.
Goals-of-Care and WOLST Process
Establishing goals of care was based on a facilitated valuebased shared decision-making model (12) . If present, advance directives were reviewed with the patient and/or surrogate decision maker with respect to life-sustaining therapies. Both physicians and the patient/surrogate contributed to the goalsof-care discussions. Consideration of individual patient factors (age, premorbid functional and cognitive status, medical comorbidities, and admission neurologic and physiologic status) and published prognostic scales led to the overall prognostic estimate for outcome (2, (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) . Taking into account the patient's known wishes, value system, personal preferences, and advance directives if available, the patient/surrogate and clinician together determined whether the best estimated prognosis was aligned with the patient's wishes and goals for an acceptable quality of life (16) .
Two attending neurointensivist physicians (J.A.F., Erroll Gordon) were involved in the majority of goals-of-care decisions and followed a similar shared decision-making process (2, (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (24) (25) (26) (27) (28) (29) (30) . Palliative care and ethics consultations were employed, but not required, for goals-of-care decision making. All patients who were made comfort care were also DNR, and WOLST occurred at a time that was convenient to the family. At the time of WOLST, any medication not offering symptom relief was discontinued and ventilated patients underwent palliative extubation with opioid and sedative medication titration to eliminate any signs of discomfort.
Patient Assessments
Admission demographic data, including medical history and premorbid functional status, were collected from the patient or surrogate upon admission. Admission clinical status was assessed using the Glasgow Coma Scale (GCS) (18) , National Institutes of Health Stroke Scale (NIHSS) (31) , and Acute Physiology and Chronic Health Evaluation II Acute Physiology Score (APACHE-II APS) (32) . Premorbid functional status was assessed using the modified Rankin Scale (mRS) (33). Details of the hospital course, including medical treatments, procedures, and complications, were recorded. Surgical intervention was defined as any operative procedure including craniotomy, hemicraniotomy, aneurysm clipping, aneurysm coiling, minimally invasive clot evacuation, or burr hole drainage of an SDH. External ventricular drainage was coded separately. Outcome measures including ICU length of stay, hospital length of stay, and costs of hospitalization (adjusted for inflation to 2,014 dollars using statistics provided by the U.S. Bureau of Labor Statistics) were provided by the hospital accounting system following hospital death or discharge. Patients' functional status was assessed with the mRS at 3 and 12 months via phone interview. If necessary, a patient's 12-month score was imputed from the 3-month score by the last observation carried forward.
Statistical Analyses
Bivariable comparisons of baseline admission and demographic data, admission clinical status, and events of hospitalization were compared between maximally treated patients with good versus poor outcomes using either the Fisher exact or Mann-Whitney U test. Next, multivariable logistic regression models were developed using the maximal therapy cohort (i.e., no WOLST patients) to predict the probability of 1) in-hospital death and 2) 12-month death/severe disability (mRS of 4-6). Models were constructed using backward elimination with an exit criterion of 0.05. Concordance indices and Hosmer-Lemeshow tests were conducted to assess the discrimination and calibration of the multivariable prediction models, respectively. The resulting multivariable models were then applied to the cohort of patients who underwent WOLST to predict the probability of in-hospital death and 12-month death/severe disability (mRS of 4-6) had the WOLST patients continued to receive maximal medical and surgical therapy. The models were also applied to each bleed type (SAH, IPH, and SDH) subgroup that underwent WOLST.
Model validation typically involves comparing the predicted outcomes to the actual outcomes; however, actual maximal therapy outcomes are not available for WOLST patients. Furthermore, a study randomizing patients to maximal therapy versus WOLST is unethical and unlikely to be conducted. The best alternative for model validation for this study is identification of a subset of the maximal therapy patients who are as similar as possible to the WOLST patients. This was achieved by propensity score matching where the propensity score reflects the likelihood that a given patient would undergo WOLST. Variables considered for the propensity score were baseline admission data, clinical status, medical comorbidities, and hospital course. Variables included in the propensity score were those with absolute standardized differences greater than 0.2 (which is equivalent to Cohen medium/large effect size). Maximal therapy patients were then propensity score matched to actual WOLST patients in a 2:1 ratio, when possible, using a 0.05 matching radius. Twenty propensity score-matched maximal therapy patients were identified, 19 of whom had 12-month functional outcomes available. The predictive models (developed on the entire maximal therapy cohort) where then applied to the propensity score-matched subgroup of the maximal therapy patients to obtain predicted probabilities of in-hospital death or 12-month death/severe disability (mRS of 4-6), which could then be compared with their actual observed outcomes to assess the predictive model performance.
All statistical analyses were conducted with SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS
Of the 383 patients enrolled for the study, 128 (33.4%) were SAH, 134 (35.0%) were SDH, and 121 (31.6%) were IPH. Twenty-six patients (6.8%) underwent WOLST, 316 patients (82.5%) continued maximal therapy and survived to discharge, and 41 patients (10.7%) continued maximal therapy and died in hospital. Among the maximally treated cohort, surgical intervention occurred in 84% of SAH patients (16% were angiographically negative), 80% of SDH patients, and 21% of IPH patients. External ventricular drainage occurred in 37% of maximally treated IPH patients, 51% of SAH patients, and 33% of SDH patients. The median time to transition to WOLST was 7 days. Fifty-three patients (13.8%) required imputation of 12-month mRS from 3-month outcome data. Twenty-nine patients were lost to follow-up after hospital discharge, resulting in an overall follow-up rate of 93.5%. Among all patients who received maximal therapy and survived to discharge, 156 (47.6%) experienced death or severe disability (mRS of 4-6) by the time of 12-month follow-up. Predictors of in-hospital death and poor 12-month mRS among intracranial hemorrhage patients who received maximal medical and surgical treatment are shown in Table 1 (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/ B623). Notably, admission neurologic and physiologic status (GCS, NIHSS, and APACHE-II APS), acute respiratory failure, use of vasopressors, less surgical intervention, and hospital complications (including pneumonia, elevated intracranial pressure [ICP], brainstem herniation, renal failure, hyperglycemia, and hypernatremia) were significantly associated with both in-hospital death and 12-month death/severe disability, despite maximal medical and surgical therapy. Table 2 presents the regression model for predicting inhospital death (c-statistic, 0.96; Hosmer-Lemeshow goodnessof-fit test, 0.98). Worse admission neurologic status (GCS), the absence of surgical/endovascular intervention, vasopressors use during hospitalization, renal failure, and a history of cardiovascular disease and/or chronic obstructive pulmonary disease (COPD) were the identified predictors of in-hospital death. Similarly, Table 3 presents the regression model for predicting 12-month death/severe disability (c-statistic, 0.92; Hosmer-Lemeshow goodness-of-fit test, 0.95). Older age, worse admission neurologic status (NIHSS), brainstem herniation, bleed type (IPH), arrhythmia, worse premorbid functional status (mRS), and history of diabetes mellitus, cancer, or COPD were the identified predictors of poor long-term outcome. To adjust for any possible confounding for treatment effect, an additional analysis was conducted where surgical intervention was forced into the final predictive model for 12-month functional outcome and it was found to be nonsignificant (adjusted odds ratio, 1.49; 95% CI, 0.57-3.88; p = 0.42).
Applying the model of in-hospital death developed on the maximal therapy patients to the WOLST cohort, a predicted probability that an individual WOLST patient would have died in-hospital had they continued maximal therapy was obtained ( Fig. 1A) . The median predicted probability of in-hospital death for the WOLST cohort had maximal therapy been continued was 35% (interquartile range [IQR], 0-76%). Thus, at least half of the WOLST patients are predicted to have had an approximately 2/3 chance (or better) of surviving to discharge had they received maximal therapy. Stratifying WOLST patients by hemorrhage type, the median predicted probability of in-hospital death was 60% (n = 13; IQR, 20-83%) for the IPH subgroup, 31% (n = 8; IQR, 6-68%) for the SDH subgroup, and only 4% (n = 2; IQR, 4-5%) for the SAH subgroup. Applying the model of 12-month death/severe disability (mRS of 4-6) developed on the maximal therapy patients to the WOLST cohort, a predicted probability that an individual WOLST patient would have a poor 12-month functional outcome had they continued maximal therapy was obtained (Fig. 1B) . The median predicted probability of 12-month death/severe disability was 98% (IQR, 88-99%). This suggests that the majority of the patients undergoing WOLST may be expected to have either died or remained severely disabled at 12 months despite continuing maximal therapy. Stratifying WOLST patients by hemorrhage type, the median predicted probability of poor 12-month functional outcome was 99% (n = 14; IQR, 88-99%) for the IPH subgroup, 97% (n = 7; IQR, 88-99%) for the SDH subgroup, and 96% (n = 3; IQR, 36-99%) for the SAH subgroup. Table 4 shows demographic and clinical differences between all patients who underwent WOLST and all those who continued maximal therapy as well as the propensity score-matched subsets. As the propensity score included a large number of variables, it is expected that balance would not be achieved on all variables individually. Overall, though very comparable to the WOLST patients, propensity-matched maximal therapy patients had more COPD, anemia, hypernatremia, elevated ICP, and/or tracheotomy and fewer had trauma, renal failure, and/or external ventricular drainage. However, these variables were infrequently observed with less than or equal to five patients in each group for the above variables. The propensity-matched cohort had similar admission NIHSS, GCS, and APACHE-II scores, rates of surgical intervention, intubation, percutaneous gastrostomy placement, and vasopressor and IV sedation use when compared with the WOLST cohort. There were slightly more SAH patients and fewer SDH patients in the propensity-matched cohort. Most of the factors that differed between the propensity-matched maximal therapy and the WOLST subgroups were not identified as significant predictors of in-hospital death or 12-month death/severe disability in the multivariable prediction models.
Applying the in-hospital death prediction model to the 20 propensity score-matched maximal therapy patients, the median predicted probability of in-hospital death was 11% (IQR, 4-43%), suggesting that the majority of these patients were predicted to survive to discharge based on the model (Fig. 2) . When examining predicted outcomes for each bleed type within the propensity-matched cohort, the median estimated probability of in-hospital death was 16% (n = 11; IQR, 6-54%) for IPH, 7% (n = 6; IQR, 4-22%) for SDH, and 4% (n = 3; IQR, 1-87%) for SAH patients. Because the patients were drawn from the maximal therapy cohort, actual hospital outcomes were able to be observed, and only 9 of 20 propensity score-matched patients were found to have died during their hospitalization. The remaining 11 patients, who were otherwise comparable to the WOLST cohort, survived to discharge.
Similarly, applying the 12-month death/severe disability prediction model to the 20 propensity score-matched maximal therapy patients, the median predicted probability of poor 12-month outcome was 97% (IQR, 83-99%), suggesting that the majority of these patients were predicted to die or have severe disability based on the model (Fig. 2) . When examining predicted outcomes for each bleed type within the propensitymatched cohort, the median estimated probability of poor 12-month functional outcome (mRS of 4-6) was 97% (n = 11; IQR, 82-99%) for IPH, 98% (n = 6; IQR, 85-99%) for SDH, and 94% (n = 3; IQR, 5-99%) for SAH patients. Sixteen of the 20 propensity score-matched maximal therapy patients had a greater than or equal to 80% predicted probability of poor 12-month functional outcomes. Indeed, all 16 of these patients were observed to have an mRS of 4-6 at 12-month follow-up. Of the four remaining patients who had lower probabilities of poor 12-month outcomes, all four were observed to have an mRS score of 0-3. Thus, the propensity score-matched validation cohort provides some evidence that the prediction models accurately estimated probabilities for 12-month death/severe disability. 
DISCUSSION
This study is one of the first to test the hypothesis that a specific, evidence-based algorithm for deciding to withdraw lifesustaining therapy in patients with aneurysmal SAH, SDH, and IPH would accurately identify patients with a high probability of death or severe disability at 1 year after hemorrhage despite aggressive treatment. From a cohort of 383 intracranial hemorrhage patients, we created prediction models based on maximal therapy patients to determine the probabilities of in-hospital death and 12-month death/severe disability (mRS of 4-6) and applied them to WOLST patients to predict outcomes had they continued receiving maximal medical and surgical therapy. The median probability of in-hospital death for the WOLST cohort was only 35%, suggesting that many of the WOLST patients were more likely to have survived than died during hospitalization if maximal therapy had been continued. In contrast, the median probability of 12-month death/severe disability was 98%, suggesting that the majority of patients who underwent WOLST were expected to have died or remained severely disabled at 12 months despite maximal therapy. Our model findings were further corroborated using propensity score matching to identify a subset of patients from among the maximal therapy group who had demographic and clinical features similar to the WOLST patients. By applying each of the prediction models to this subset, we found that the estimated probabilities of in-hospital death and 12-month death/severe disability were similar to the actual observed outcomes, validating a good model performance. Among the propensity score-matched patients, there was only a modest probability of in-hospital death (median, 11%) but high probability of 12-month death/severe disability (median, 97%). This supports the idea that it is reasonable to apply our prediction model (developed in the 316 patients in the maximal therapy cohort) to the 26 patients in the WOLST cohort to determine the probability of in-hospital death or 12-month outcome had maximal therapy been continued. The model was equally effective in predicting poor 12-month function across hemorrhage subgroups (IPH, SAH, and SDH). This is likely because the factors that went into the multivariable model apply broadly to patients with neurocritical illness. For example, admission NIHSS, premorbid functional status, herniation, history of medical comorbidities (COPD, diabetes mellitus, and cancer), and medical complications such as arrhythmia are common to patients with IPH, SAH, and SDH. Overall, these data suggests that WOLST may not represent a self-fulfilling prophecy with regard to long-term functional outcomes.
Strengths of this study included the large cohort size, longitudinally collected data, comprehensive set of admission and hospital variables, and long-term 12-month follow-up. Our findings demonstrate that consideration of the anticipated patient recovery is a critical component in the evaluation of prognostic models. Using a primary outcome of in-hospital death, WOLST may indeed represent a self-fulfilling prophecy, as treatment regimens are withheld from patients who might otherwise survive to discharge. However, given the long-term impact of severe brain injury on functional outcomes, early endpoints such as in-hospital mortality may be insufficient for discussions involving patient prognosis. Although international meta-analysis data on IPH reports a 1-month case fatality of 40.4%, this rate increases to 54.7% by 1-year posthemorrhage (24) . Independent functional outcomes remained poor, with observed rates of between 12% and 39% (24) . Similarly, long-term cognitive and functional deficits are common across types of intracranial hemorrhage (25) . Consideration of patient outcomes beyond the immediate hospitalization is essential to discussions of goals of care in the neurocritically ill.
Overall, 6.8% of all patients underwent WOLST and died, whereas 10.7% of all patients received maximal medical and/ or surgical therapy and died in hospital. Compared with other studies of intracranial hemorrhage (11), our group was aggressive with treatment and conservative with WOLST. Even those patients who ultimately underwent WOLST received aggressive Survey results suggest that many physicians are overly pessimistic and inaccurate in predicting outcome in neurocritically ill patients (4) . In a cohort study that assessed a model for prediction of outcome after IPH, inclusion of a variable for WOLST negated all other factors in predicting outcome (4). Similar results have been found in studies of traumatic brain injury (11, 26) and SAH patients (27) . Additional studies of IPH patients have found that early DNR orders and/or WOLST doubled the risk of short-and long-term mortality, even after adjusting for known predictors of mortality (age, gender, ethnicity, GCS, IPH volume, intraventricular hemorrhage, and infratentorial hemorrhage) (28) . Though one study found that a DNR order placed within the first 24 hours of IPH did not alter 1-year outcomes compared with controls, the authors concede that DNR orders were not the same as WOLST and DNR status did not impact the level of medical care provided (23) . Hence, our study more directly addresses whether withdrawal of therapy represents a self-fulfilling prophecy.
This investigation also provides a thorough analysis of demographic and clinical factors associated with the WOLST decision (Table 4 ). Other studies of intracranial hemorrhage and traumatic brain injury have sought to identify the independent predictors of the WOLST decision. Herniation is a significant predictor of WOLST following traumatic brain injury (26, 29) , whereas older age, neurologic status (pupillary reactivity), cardiac arrest, and elevated ICP crisis have also been identified (26) . Similarly, older age and poor clinical grade on presentation predicted WOLST in analyses of both IPH and aneurysmal SAH (27, 30) . IPH bleed type has previously been associated with WOLST (34) . Potential gender and ethnic associations with WOLST have also been identified (35) , as part of a retrospective review. Though these studies were able to identify factors that contributed to the WOLST decision, none aimed to determine whether this decision led to a self-fulfilling fatal outcome or if WOLST was applied in an accurate manner to patients who were likely to have poor outcomes irrespective of treatment.
Certain limitations of this study should be noted. This was a retrospective cohort study using prospectively collected data. A randomized trial of the option of WOLST versus maximal therapy would present ethical challenges and be difficult to conduct. As a single-center study, the findings presented here may not be generalizable to other institutions with varying patient populations or clinical practices regarding WOLST. Although a thorough registry of patient-centered variables were collected as part of the study, our group did not specifically collect data on the values and attitudes of patients, families, or clinicians making end-of-life decisions. These data might be heterogeneous given the diverse racial, ethnic, and religious population at our center and prove challenging to analyze. However, since the WOLST and the maximal therapy cohorts followed similar initial clinical management plans at a single institution, this served to limit heterogeneity between comparison groups. Though we did attempt to adjust for treatment effect, and the maximally treated cohort appeared to have high rates of aggressive interventions (including neurosurgical operations, intubation, and external ventricular drainage), we found that less surgical intervention was associated with in-hospital death among "maximally treated" patients. However, surgical intervention was not significantly associated with 12-month functional outcomes in multivariable analysis. Thus, there may be some treatment bias even in the "maximally treated" cohort though this did not influence the primary 12-month outcome. Diagnostic and/or therapeutic advances in the coming years might also alter our results, since factors affecting the prediction models may change over time.
Given the low number of outcomes and WOLST events for any single diagnosis, it was necessary to combine patients across types of intracranial hemorrhage in order to perform the described analyses. Although a preferable approach would be to analyze each bleed type separately, combining diagnoses represents a "real-world" scenario where neurointensivists may encounter a spectrum of neurologic injury necessitating consideration of the WOLST decision. Furthermore, when stratifying results according to hemorrhage type, we observed that the model showed similar probabilities for 12-month functional outcome for each hemorrhage type when compared with the combined cohort.
Last, although the majority of WOLST patients from this cohort were predicted to experience poor 12-month outcomes, approximately 20% (4 of 20) of the validation cohort of propensity score-matched maximal therapy patients were projected to have modified Rankin scores between 0 and 3 (no disability to disabled but able to walk without assistance) at 12 months. Not all propensity score-matched maximal therapy patients had a high probability of 12-month mRS of 4-6 (despite having a highly probability of WOLST); however, we did not assess other important outcomes such as quality of life, cognition, and activities of daily living, which may be impaired in these patients. This highlights the importance of considering all factors, including patient and family expectations with regard to goals of care. A larger multicenter study would be necessary to better characterize WOLST, the interplay of patient and physician factors, and the outcomes of death and severe disability following each individual type of hemorrhage. Additionally, a validation study evaluating the performance of our multivariable model for 12-month mRS of 4-6 in a separate cohort of maximally treated general neuro-ICU, SAH, IPH, or SDH patients should be pursued. If our results are confirmed in an independent cohort, this may allow practitioners to offer patients and families a more precise estimate of long-term outcomes and facilitate goals-of-care discussions.
CONCLUSIONS
This study found that although some intracranial hemorrhage patients who underwent WOLST may have survived to discharge had maximal therapy been continued, the majority of patients would have died or remained severely disabled at 12 months with continued treatment. As evidenced in this study, WOLST may be applied in a rational and accurate manner among intracranial hemorrhage patients and may not represent a self-fulfilling prophecy. Larger studies are necessary to better identify patients appropriate for WOLST, thereby allowing goals-of-care discussions to be held at an earlier time to potentially shorten length of stay, lower hospital costs, and reduce patient and family suffering.
